COVID-19 Vaccine Uptake and Intentions Following US Food and Drug Administration Approval of the Pfizer-BioNTech COVID-19 Vaccine

Published in: JAMA Internal Medicine (2022). doi: 10.1001/jamainternmed.2022.0761

Posted on on April 27, 2022

by Aaron M. Scherer, Andrew M. Parker, Courtney A. Gidengil, Amber M. Gedlinske, Natoshia M. Askelson, Christine A. Petersen, Megan Lindley

Read More

Access further information on this document at JAMA Network

This article was published outside of RAND. The full text of the article can be found at the link above.

Despite the availability of safe and effective COVID-19 vaccines, 25% of American adults remained partially vaccinated or unvaccinated against COVID-19 at the beginning of 2022. Lack of a formally approved COVID-19 vaccine was a common reason given for nonvaccination in polls prior to US Food and Drug Administration (FDA) approval of the biologics license application-also called full approval-for the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine. Understanding the repercussions for vaccination intentions after FDA full approval is important for informing vaccination interventions and policy in future infectious disease outbreaks. The primary objective of this survey with unvaccinated US adults was to assess vaccination intentions in response to full approval of the BNT162b2 COVID-19 vaccine and any demographic associations with these intentions.

This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.